PL3405178T3 - Preparaty/kompozycje zawierające inhibitor btk - Google Patents

Preparaty/kompozycje zawierające inhibitor btk

Info

Publication number: PL3405178T3
Authority: PL; Poland
Prior art keywords: preparations; compositions containing; btk inhibitor; containing btk; inhibitor
Prior art date: 2016-01-19

Application number

PL17700821.6T

Other languages

English (en)

Inventor

Manish Kumar Gupta

Parikshit Rameshrao Kulkarni

Binuraj KRISHNAN NAIR

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-19

Filing date

2017-01-18

Publication date

2025-11-12

2017-01-18 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2025-11-12 Publication of PL3405178T3 publication Critical patent/PL3405178T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Hematology (AREA)
Inorganic Chemistry (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Obesity (AREA)
Transplantation (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL17700821.6T 2016-01-19 2017-01-18 Preparaty/kompozycje zawierające inhibitor btk PL3405178T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN201621001987		2016-01-19
PCT/EP2017/050964 WO2017125424A1 (en)	2016-01-19	2017-01-18	Formulations/compositions comprising a btk inhibitor

Publications (1)

Publication Number	Publication Date
PL3405178T3 true PL3405178T3 (pl)	2025-11-12

Family

ID=57851068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17700821.6T PL3405178T3 (pl)	2016-01-19	2017-01-18	Preparaty/kompozycje zawierające inhibitor btk

Country Status (25)

Country	Link
US (3)	US20190290650A1 (pl)
EP (2)	EP4663247A2 (pl)
JP (3)	JP7336195B2 (pl)
KR (2)	KR20250025518A (pl)
CN (2)	CN108472258B (pl)
AR (1)	AR107392A1 (pl)
AU (1)	AU2017208473B2 (pl)
BR (1)	BR112018014540B1 (pl)
CA (1)	CA3008576A1 (pl)
DK (1)	DK3405178T3 (pl)
EA (1)	EA201891664A1 (pl)
ES (1)	ES3041841T3 (pl)
FI (1)	FI3405178T3 (pl)
HK (2)	HK1259433A1 (pl)
HR (1)	HRP20251152T1 (pl)
LT (1)	LT3405178T (pl)
MA (1)	MA43650B1 (pl)
MX (2)	MX2018008772A (pl)
PL (1)	PL3405178T3 (pl)
PT (1)	PT3405178T (pl)
RS (1)	RS67236B1 (pl)
SI (1)	SI3405178T1 (pl)
SM (1)	SMT202500360T1 (pl)
TW (1)	TWI794153B (pl)
WO (1)	WO2017125424A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9296753B2 (en)	2012-06-04	2016-03-29	Pharmacyclics Llc	Crystalline forms of a Bruton's tyrosine kinase inhibitor
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
PL3405178T3 (pl) *	2016-01-19	2025-11-12	Janssen Pharmaceutica Nv	Preparaty/kompozycje zawierające inhibitor btk
JP7590810B2 (ja)	2016-10-06	2024-11-27	ヤンセンファーマシューティカエヌ．ベー．	Ｂｔｋ阻害剤を調製するための方法および中間体
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
WO2019142207A1 (en)	2018-01-20	2019-07-25	Natco Pharma Limited	Pharmaceutical compositions comprising ibrutinib
EP3575300A1 (en)	2018-05-31	2019-12-04	Apotex Inc.	Novel crystalline forms of ibrutinib
KR20250125432A (ko)	2018-06-15	2025-08-21	얀센 파마슈티카 엔브이	이브루티닙을 포함하는 제형/조성물
US10688050B1 (en) *	2018-12-21	2020-06-23	Synthon B.V.	Pharmaceutical composition comprising ibrutinib
US11504378B2 (en) *	2019-10-21	2022-11-22	Celgene Corporation	Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4327725A (en)	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US4624848A (en)	1984-05-10	1986-11-25	Ciba-Geigy Corporation	Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en)	1987-07-27	1990-11-06	Mcneilab, Inc.	Oral sustained release acetaminophen formulation and process
IL92966A (en)	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
ES2111065T5 (es)	1991-04-16	2005-06-16	Nippon Shinyaku Company, Limited	Procedimiento para producir una dispersion solida.
CA2122479C (en)	1991-11-22	1998-08-25	Richard John Dansereau	Risedronate delayed-release compositions
US5461140A (en)	1992-04-30	1995-10-24	Pharmaceutical Delivery Systems	Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en)	1992-06-23	1994-06-28	Multi-Comp, Inc.	Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de)	1992-10-16	2003-07-31	Nippon Shinyaku Co., Ltd.	Verfahren zur herstellung von wachsmatrizes
US5686105A (en)	1993-10-19	1997-11-11	The Procter & Gamble Company	Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en)	1994-04-22	2001-12-04	Sugen, Inc.	Megakaryocytic protein tyrosine kinases
KR19990014865A (ko)	1995-05-17	1999-02-25	피터 이. 브래이브맨	소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6395300B1 (en)	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US6465014B1 (en)	2001-03-21	2002-10-15	Isp Investments Inc.	pH-dependent sustained release, drug-delivery composition
AU2004271192B2 (en)	2003-09-03	2011-11-17	Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services	Methods for identifying, diagnosing, and predicting survival of lymphomas
EP2529621B1 (en)	2006-09-22	2016-10-05	Pharmacyclics LLC	Inhibitors of bruton's tyrosine kinase
CN110801454A (zh) *	2011-10-19	2020-02-18	药品循环有限责任公司	布鲁顿酪氨酸激酶(btk)抑制剂的用途
US9296753B2 (en) *	2012-06-04	2016-03-29	Pharmacyclics Llc	Crystalline forms of a Bruton's tyrosine kinase inhibitor
WO2014004707A1 (en) *	2012-06-29	2014-01-03	Principia Biopharma Inc.	Formulations comprising ibrutinib
JP2016512549A (ja) *	2013-03-14	2016-04-28	ファーマサイクリックスエルエルシー	ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
WO2015071432A1 (en) *	2013-11-14	2015-05-21	Sandoz Ag	Pharmaceutical compositions of ibrutinib
CN104523695A (zh) *	2014-11-12	2015-04-22	广东东阳光药业有限公司	一种治疗过度增生性疾病的药物组合物
PL3405178T3 (pl) *	2016-01-19	2025-11-12	Janssen Pharmaceutica Nv	Preparaty/kompozycje zawierające inhibitor btk
EA201891440A1 (ru) *	2016-01-19	2018-12-28	Янссен Фармацевтика Нв	Составы/композиции, содержащие ингибитор btk

2017
- 2017-01-18 PL PL17700821.6T patent/PL3405178T3/pl unknown
- 2017-01-18 CA CA3008576A patent/CA3008576A1/en active Pending
- 2017-01-18 FI FIEP17700821.6T patent/FI3405178T3/fi active
- 2017-01-18 DK DK17700821.6T patent/DK3405178T3/da active
- 2017-01-18 US US16/071,453 patent/US20190290650A1/en not_active Abandoned
- 2017-01-18 ES ES17700821T patent/ES3041841T3/es active Active
- 2017-01-18 MX MX2018008772A patent/MX2018008772A/es unknown
- 2017-01-18 LT LTEPPCT/EP2017/050964T patent/LT3405178T/lt unknown
- 2017-01-18 EP EP25183977.5A patent/EP4663247A2/en active Pending
- 2017-01-18 MA MA43650A patent/MA43650B1/fr unknown
- 2017-01-18 BR BR112018014540-8A patent/BR112018014540B1/pt active IP Right Grant
- 2017-01-18 WO PCT/EP2017/050964 patent/WO2017125424A1/en not_active Ceased
- 2017-01-18 RS RS20250946A patent/RS67236B1/sr unknown
- 2017-01-18 KR KR1020257004789A patent/KR20250025518A/ko active Pending
- 2017-01-18 CN CN201780006739.5A patent/CN108472258B/zh active Active
- 2017-01-18 HK HK19101837.4A patent/HK1259433A1/zh unknown
- 2017-01-18 SI SI201731626T patent/SI3405178T1/sl unknown
- 2017-01-18 AU AU2017208473A patent/AU2017208473B2/en active Active
- 2017-01-18 EP EP17700821.6A patent/EP3405178B1/en active Active
- 2017-01-18 EA EA201891664A patent/EA201891664A1/ru unknown
- 2017-01-18 HK HK19101845.4A patent/HK1259441A1/zh unknown
- 2017-01-18 HR HRP20251152TT patent/HRP20251152T1/hr unknown
- 2017-01-18 SM SM20250360T patent/SMT202500360T1/it unknown
- 2017-01-18 JP JP2018556012A patent/JP7336195B2/ja active Active
- 2017-01-18 PT PT177008216T patent/PT3405178T/pt unknown
- 2017-01-18 KR KR1020187023229A patent/KR20180102150A/ko active Pending
- 2017-01-18 CN CN202210154359.9A patent/CN114681462A/zh active Pending
- 2017-01-19 AR ARP170100142A patent/AR107392A1/es unknown
- 2017-01-19 TW TW106101787A patent/TWI794153B/zh not_active IP Right Cessation
2018
- 2018-07-17 MX MX2022006817A patent/MX2022006817A/es unknown
2021
- 2021-02-11 US US17/174,305 patent/US20210169888A1/en not_active Abandoned
2022
- 2022-04-07 JP JP2022063752A patent/JP7565971B2/ja active Active
- 2022-11-22 US US17/992,348 patent/US20230364090A1/en not_active Abandoned
2024
- 2024-06-05 JP JP2024091441A patent/JP2024138243A/ja active Pending

Also Published As

Publication number	Publication date
EA201891664A1 (ru)	2019-02-28
HK1259441A1 (zh)	2019-11-29
PT3405178T (pt)	2025-10-06
HK1259433A1 (zh)	2019-11-29
AU2017208473B2 (en)	2022-04-21
SI3405178T1 (sl)	2025-11-28
JP2022105006A (ja)	2022-07-12
RS67236B1 (sr)	2025-10-31
DK3405178T3 (da)	2025-09-22
FI3405178T3 (fi)	2025-09-30
US20210169888A1 (en)	2021-06-10
MA43650B1 (fr)	2025-09-30
TW201737918A (zh)	2017-11-01
MA43650A (fr)	2018-11-28
LT3405178T (lt)	2025-11-10
SMT202500360T1 (it)	2025-11-10
BR112018014540A2 (pt)	2018-12-11
AU2017208473A1 (en)	2018-07-12
WO2017125424A1 (en)	2017-07-27
HRP20251152T1 (hr)	2025-12-05
BR112018014540B1 (pt)	2024-02-27
MX2018008772A (es)	2018-11-09
JP7565971B2 (ja)	2024-10-11
CN108472258A (zh)	2018-08-31
US20190290650A1 (en)	2019-09-26
JP2024138243A (ja)	2024-10-08
MX2022006817A (es)	2022-07-11
JP2019506450A (ja)	2019-03-07
KR20180102150A (ko)	2018-09-14
CN108472258B (zh)	2024-05-24
EP4663247A2 (en)	2025-12-17
US20230364090A1 (en)	2023-11-16
TWI794153B (zh)	2023-03-01
AR107392A1 (es)	2018-04-25
CN114681462A (zh)	2022-07-01
EP3405178A1 (en)	2018-11-28
CA3008576A1 (en)	2017-07-27
JP7336195B2 (ja)	2023-08-31
KR20250025518A (ko)	2025-02-21
ES3041841T3 (en)	2025-11-14
EP3405178B1 (en)	2025-07-02

Publication	Publication Date	Title
IL263586A (en)	2019-01-31	Inhibitors of the menin-mll interaction
EP3534968A4 (en)	2020-07-01	ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
MA46458A (fr)	2019-08-14	Compositions debacillus thuringiensis
EP3563742A4 (en)	2020-08-05	CLEANING DEVICE
DK3529248T3 (da)	2020-09-14	Farmaceutiske sammensætninger
DK3495023T3 (da)	2020-07-20	Semifluorerede forbindelser og sammensætninger deraf
EP3485790A4 (en)	2020-09-16	CLEANING DEVICE
EP3493800A4 (en)	2020-04-08	CANNABIS
PL3405178T3 (pl)	2025-11-12	Preparaty/kompozycje zawierające inhibitor btk
DK3092256T3 (da)	2022-06-20	Forbindelser og sammensætninger til immunterapi
DK3892302T3 (da)	2023-11-13	Sammensætninger indeholdende ibrutinib
DK3416996T3 (da)	2020-07-06	Hærdelig sammensætning
DK3494119T3 (da)	2024-12-02	Forbindelser og sammensætninger og anvendelser deraf
EP3536211A4 (en)	2020-07-22	CLEANING DEVICE
DK3250182T3 (da)	2023-06-26	Dispergible sammensætninger
DK3116475T3 (da)	2020-12-07	Dopa-decarboxylasehæmmersammensætninger
DK3528902T3 (da)	2021-07-05	Ringegelsammensætning
PT3261437T (pt)	2019-11-29	Compostos e composições fungicidas
EP3554470A4 (en)	2020-02-26	COSMETIC COMPOSITIONS
EP3560512A4 (en)	2020-07-22	COMPOSITION OF VACCINE AGAINST ZONA
DK3197936T3 (da)	2025-09-29	Silanfunktionaliserede forbindelser og sammensætninger deraf
EP3480228A4 (en)	2020-03-11	COMPOSITION
IL264445A (en)	2019-02-28	Compounds and compositions and uses thereof
DK3528791T3 (da)	2024-01-29	Dispergible sammensætninger
EP3556804A4 (en)	2019-11-13	COMPOSITION